相关实验视频

Updated: May 26, 2025

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms

Published on: March 15, 2024

糖尿病技术趋势:对最新创新的回顾

Erika L Lundgrin^1,2,3, Clare A Kelly^1,2, Natalie Bellini^1,2

¹Diabetes and Metabolic Care Center, University Hospitals, Cleveland, OH 44106, USA.

The Journal of clinical endocrinology and metabolism

|February 25, 2025

概括

最近的糖尿病管理技术,包括连续血糖监测器和自动胰岛素输送,改善了1型和2型糖尿病患者的血糖控制和生活质量.

科学领域:

内分泌学在内分泌学.
医疗技术医疗技术医学技术
数字健康数字健康

背景情况:

糖尿病管理已经看到技术工具的快速增长,如连续血糖监测器和自动化胰岛素输送系统.
这些设备的可用性增加正在推动它们的采用,以改善糖尿病护理.
本综述侧重于美国最近的创新,旨在改善患者的治疗结果.

研究的目的:

审查美国糖尿病管理领域的最新技术创新.
突出提升患者结果和生活质量的进步.
为医疗保健提供者和患者提供有关糖尿病技术不断变化的信息.

主要方法:

在主要数据库 (Medline,PubMed,ScienceDirect,Embase,Cochrane Library) 中进行了系统的文献搜索.
搜索的重点是2014年至2024年间发表的同行评审文章.
包括专门研究糖尿病护理中技术辅助治疗的研究.

主要成果:

糖尿病技术已经大大降低了血糖监测和胰岛素输送的负担.
临床试验表明,使用这些先进技术可以提高精度和血糖结果.
糖尿病技术的使用与提高患者的自我效能和改善1型和2型糖尿病患者的生活质量有关.

结论:

糖尿病技术显著提高了血糖控制,患者满意度和整体生活质量.
评估技术的作用对于1型和2型糖尿病管理至关重要.
在将技术整合到糖尿病护理中时,个性化治疗目标至关重要.

关键词:

援助援助援助援助在CGM中,CGM是指CGM.糖尿病糖尿病患者糖尿病患者胰岛素的胰岛素胰岛素是什么胰岛素的胰岛素可以技术技术的技术技术的技术.

更多相关视频

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Simple Continuous Glucose Monitoring in Freely Moving Mice

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

相关概念视频

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...